GOVX
GeoVax Labs, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-41/100
Last price
0.29
▼ 0.03 (8.32%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.31
Prev close
0.32
Day high
0.33
Day low
0.28
Volume
1.63M
Market cap
$2.91M
P/E (TTM)
—
52W range
0.28 – 15.75
Day trading desk
Gap from prior close
-3.78%
Prior close 0.32
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
4.98%
0.29 – 0.31
Position in range
0%
Near session low
ATR (14D)
0.04
13.03% of price
Prior day high
0.46
PDH
Prior day low
0.31
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 748.80K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-17.90%
-19.8%
1M
-40.17%
-41.3%
3M
-75.09%
-79.6%
6M
-76.12%
-94.3%
YTD
-93.24%
-107.5%
1Y
-98.01%
-114.4%
3Y
-99.85%
-182.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GOVX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.21K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 17, 25 | SPENCER JOHN N JR Director |
BUY | 10.00K | $5.50K | Direct |
| Aug 7, 25 | MCKEE KELLY T JR. Officer |
BUY | 1.11K | $742 | Direct |
| Apr 10, 25 | SPENCER JOHN N JR Director |
BUY | 10.00K | $9.80K | Direct |
| Apr 10, 25 | SHARKEY JOHN W PH.D. Officer |
BUY | 6.00K | $5.94K | Direct |
| Apr 1, 25 | DODD DAVID A Chief Executive Officer |
BUY | 10.00K | $10.80K | Direct |
| Mar 31, 25 | REYNOLDS MARK W Chief Financial Officer |
BUY | 6.80K | $7.34K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DODD DAVID A |
Chief Executive Officer | 36.66K | Purchase |
MCKEE KELLY T JR. |
Officer | 3.49K | Purchase |
REYNOLDS MARK W |
Chief Financial Officer | 14.01K | Purchase |
SHARKEY JOHN W PH.D. |
Officer | 6.19K | Purchase |
SPENCER JOHN N JR |
Director | 21.40K | Purchase |
Fundamentals
Market cap$2.91M
Enterprise value$-694.25K
Revenue (TTM)$0
Gross profit$-15.05M
EBITDA$-20.47M
Net income$-20.43M
EPS (TTM)$-8.84
Free cash flow$-10.82M
Total cash$3.14M
Total debt$323.14K
Book value / share$0.24
Shares outstanding10.10M
Float6.92M
Short % of float4.94%
Dividend yield0.00%
Beta (5Y)3.69
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.34
PEG ratio—
Price / sales—
Price / book1.21
EV / revenue—
EV / EBITDA0.03
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-891.59%
Return on assets-256.80%
Debt / equity18.35
Current ratio1.54
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.49M | $3.95M | $0 | $81.53K | -37.1% |
| Operating revenue | $2.49M | $3.95M | $0 | $81.53K | -37.1% |
| Research & development | $18.12M | $23.71M | $20.72M | $9.12M | -23.6% |
| Selling, general & admin | $6.01M | $5.39M | $6.02M | $4.99M | +11.5% |
| Total operating expense | $24.13M | $29.10M | $26.74M | $14.11M | -17.1% |
| Operating income | -$21.64M | -$25.14M | -$26.74M | -$14.03M | +13.9% |
| Net interest income | $174.28K | $151.98K | $776.18K | $7.44K | +14.7% |
| Pre-tax income | -$21.46M | -$24.99M | -$25.97M | -$14.02M | +14.1% |
| Net income | -$21.46M | -$24.99M | -$25.97M | -$14.02M | +14.1% |
| Net income to common | -$21.46M | -$24.99M | -$25.97M | -$14.02M | +14.1% |
| Basic EPS | -22.40 | -120.46 | -357.25 | -311.25 | +81.4% |
| Diluted EPS | -22.40 | -120.46 | -357.25 | -311.25 | +81.4% |
| EBIT | -$21.46M | -$24.97M | -$25.97M | -$14.03M | +14.0% |
| EBITDA | -$21.40M | -$24.88M | -$25.89M | -$13.97M | +14.0% |
| Basic shares | 958.44K | 207.48K | 72.69K | 45.26K | +361.9% |
| Diluted shares | 958.44K | 207.48K | 72.69K | 45.26K | +361.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.09M | $5.51M | $6.45M | $27.61M | -44.0% |
| Cash & short-term investments | $3.09M | $5.51M | $6.45M | $27.61M | -44.0% |
| Total current assets | $5.31M | $7.93M | $7.89M | $28.94M | -33.0% |
| Property, plant & equipment | $940.27K | $149.97K | $209.69K | $234.91K | +527.0% |
| Goodwill & intangibles | $50.00K | $60.00K | $70.00K | $80.00K | -16.7% |
| Total assets | $6.34M | $8.16M | $9.28M | $31.35M | -22.2% |
| Total current liabilities | $1.94M | $3.11M | $3.52M | $4.75M | -37.7% |
| Total debt | $843.17K | $0 | — | — | — |
| Total liabilities | $2.52M | $3.11M | $3.52M | $4.75M | -19.0% |
| Retained earnings | -$150.82M | -$129.36M | -$104.36M | -$78.40M | -16.6% |
| Shareholder equity | $3.83M | $5.05M | $5.76M | $26.60M | -24.2% |
| Working capital | $3.38M | $4.83M | $4.37M | $24.19M | -30.0% |
| Net tangible assets | $3.78M | $4.99M | $5.69M | $26.60M | -24.3% |
| Shares issued | 1.73M | 421.48K | 79.09K | 70.23K | +311.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$21.46M | -$24.99M | -$25.97M | -$14.02M | — | +14.1% |
| Depreciation & amortisation | $68.76K | $95.37K | $74.17K | $56.28K | — | -27.9% |
| Stock-based compensation | $1.12M | $528.64K | $1.07M | $902.07K | — | +110.9% |
| Change in working capital | -$1.19M | -$307.23K | -$356.00K | -$5.97M | — | -288.3% |
| Operating cash flow | -$21.47M | -$24.68M | -$25.17M | -$19.03M | — | +13.0% |
| Capital expenditure | -$27.61K | -$20.65K | -$48.95K | -$134.26K | — | -33.7% |
| Investing cash flow | -$27.61K | -$20.65K | -$48.95K | -$134.26K | — | -33.7% |
| Share buybacks | — | — | — | $0 | -$1.00K | — |
| Financing cash flow | $19.08M | $23.75M | $4.06M | $35.35M | — | -19.7% |
| Free cash flow | -$21.50M | -$24.70M | -$25.22M | -$19.16M | — | +12.9% |
| End cash position | $3.09M | $5.51M | $6.45M | $27.61M | — | -44.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $852.28K | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $852.28K | — | — |
| Research & development | $3.11M | $3.90M | $2.99M | $5.04M | $4.73M | — | -20.3% |
| Selling, general & admin | $1.33M | $1.37M | $1.45M | $1.33M | $1.54M | — | -2.8% |
| Total operating expense | $4.44M | $5.27M | $4.44M | $6.37M | $6.27M | — | -15.8% |
| Operating income | -$4.44M | -$5.27M | -$4.44M | -$6.37M | -$5.42M | — | +15.8% |
| Net interest income | $15.49K | $10.96K | $23.33K | $54.30K | $49.12K | — | +41.4% |
| Pre-tax income | -$4.43M | -$5.26M | -$4.42M | -$6.32M | -$5.37M | — | +15.9% |
| Net income | -$4.43M | -$5.26M | -$4.42M | -$6.32M | -$5.37M | — | +15.9% |
| Net income to common | -$4.43M | -$5.26M | -$4.42M | -$6.32M | -$5.37M | — | +15.9% |
| Basic EPS | -0.97 | -2.62 | — | -7.75 | -8.75 | -11.20 | +63.0% |
| Diluted EPS | -0.97 | -2.62 | — | -7.75 | -8.75 | -11.20 | +63.0% |
| EBIT | -$4.44M | -$5.27M | -$4.42M | -$6.32M | -$5.42M | — | +15.8% |
| EBITDA | -$4.43M | -$5.26M | -$4.40M | -$6.30M | -$5.40M | — | +15.8% |
| Basic shares | 4.56M | 2.01M | — | 811.49K | 613.71K | 478.19K | +127.3% |
| Diluted shares | 4.56M | 2.01M | — | 811.49K | 613.71K | 478.19K | +127.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.14M | $1.27M | $3.09M | $5.01M | $3.09M | +147.2% |
| Cash & short-term investments | $3.14M | — | — | — | — | — |
| Total current assets | $4.18M | $2.43M | $5.31M | $6.52M | $5.14M | +71.7% |
| Property, plant & equipment | $397.51K | $481.14K | $940.27K | $127.06K | $143.86K | -17.4% |
| Goodwill & intangibles | $50.00K | $50.00K | $50.00K | $50.00K | $60.00K | 0.0% |
| Total assets | $4.64M | $2.98M | $6.34M | $6.73M | $5.35M | +55.7% |
| Total current liabilities | $2.71M | $2.29M | $1.94M | $1.82M | $2.53M | +18.4% |
| Total debt | $323.14K | $394.57K | $843.17K | — | — | -18.1% |
| Total liabilities | $2.88M | $2.49M | $2.52M | $1.82M | $2.53M | +15.8% |
| Retained earnings | -$160.51M | -$156.08M | -$150.82M | -$146.40M | -$140.08M | -2.8% |
| Shareholder equity | $1.76M | $493.77K | $3.83M | $4.91M | $2.82M | +256.6% |
| Working capital | $1.46M | $139.78K | $3.38M | $4.69M | $2.61M | +946.5% |
| Net tangible assets | $1.71M | $443.77K | $3.78M | $4.86M | $2.76M | +285.5% |
| Shares issued | 5.21M | 2.82M | 1.73M | 1.19M | 636.98K | +84.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$4.43M | -$5.26M | -$4.42M | -$6.32M | -$5.37M | — | +15.9% |
| Depreciation & amortisation | $12.08K | $12.08K | $18.23K | $16.80K | $16.80K | — | 0.0% |
| Stock-based compensation | $163.75K | $219.32K | $252.12K | $277.55K | $292.74K | — | -25.3% |
| Change in working capital | $592.65K | $1.49M | -$813.71K | -$187.55K | $725.84K | — | -60.3% |
| Operating cash flow | -$3.66M | -$3.54M | -$4.96M | -$6.21M | -$4.33M | — | -3.4% |
| Capital expenditure | — | — | — | — | -$10.72K | -$16.89K | — |
| Investing cash flow | $0 | $0 | $0 | $0 | -$10.72K | — | — |
| Financing cash flow | $5.53M | $1.72M | $3.04M | $8.13M | $209 | — | +220.8% |
| Free cash flow | -$3.66M | -$3.54M | -$4.96M | -$6.21M | -$4.35M | — | -3.4% |
| End cash position | $3.14M | $1.27M | $3.09M | $5.01M | $3.09M | — | +147.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.16 | -0.97 | +55.0% |
| Mar 2026 | -0.85 | -2.62 | -210.1% |
| Dec 2025 | -5.35 | — | — |
| Sep 2025 | -6.63 | -7.75 | -17.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.09 | 1 | $0 | 0.0% |
| Next quarter | -1.20 | 1 | $0 | 0.0% |
| Current year | -5.14 | 1 | $0 | -100.0% |
| Next year | -2.86 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$10.00
High target$10.00
Low target$10.00
Implied upside3309.48%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders0.03%
Held by institutions9.77%
Institutions holding20
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.34
-13.02% from price
SMA 20
0.37
-22.79% from price
SMA 50
0.55
-47.44% from price
SMA 100
1.02
-71.29% from price
SMA 200
1.64
-82.35% from price
EMA 12
0.35
-15.14% from price
EMA 26
0.42
-30.55% from price
EMA 50
0.58
-49.36% from price
RSI (14)
20.1
Oversold
MACD (12,26,9)
-0.08
Hist 0.01
ATR (14)
0.04
13.22% of price
Realised vol 30D
76.8%
Annualised
Bollinger upper
0.48
20, 2σ
Bollinger lower
0.27
20, 2σ
50 / 200 cross
Death
0.55 vs 1.64
Trend bias
Below 200
-82.35%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.77
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
76.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-98.1%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.04
13.22% of price
Beta (reported)
3.69
5Y monthly, from filing
Short interest
Shares short
498.70K
Prior 182.36K
Change vs prior
+173.5%
Shorts adding
% of float
4.94%
Normal
% of shares out
4.94%
Against total outstanding
Days to cover
0.4
Liquid
Float
6.92M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 26 | Noble Capital Markets | MAINTAINED | Outperform | Outperform |
| Apr 16, 26 | D. Boral Capital | MAINTAINED | Hold | Hold |
| Feb 19, 26 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Jan 21, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 19, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 26, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 7, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 29, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 17, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jun 16, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| May 2, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Apr 16, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateSep 25, 2020
Last split1:25
Split dateJan 12, 2026
SEC filings
Offering Registrations
S-1 · 2026-09-17
Corporate Changes & Voting Matters
8-K · 2026-09-10
Proxy Statements
PRE 14A · 2026-08-31
Corporate Changes & Voting Matters
8-K · 2026-08-28
Periodic Financial Reports
10-Q · 2026-07-27
Corporate Changes & Voting Matters
8-K · 2026-07-10
Corporate Changes & Voting Matters
8-K · 2026-06-17
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-06-01
Headlines
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
NewMediaWire · 20h ago
GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States
NewMediaWire · 8d ago
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
NewMediaWire · 16d ago
GeoVax Confirms Bundibugyo Ebola Vaccine Construct
NewMediaWire · 21d ago
GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial
NewMediaWire · 23d ago
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
NewMediaWire · 27d ago
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply
NewMediaWire · 28d ago
GeoVax Announces a Warrant Inducement Transaction
NewMediaWire · 42d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.